Efficacy and tolerability of micafungin monotherapy for candidemia and deep-seated candidiasis in adults with cancer.
Antimicrob Agents Chemother
; 58(6): 3526-9, 2014 Jun.
Article
in En
| MEDLINE
| ID: mdl-24637687
ABSTRACT
The response rate among 58 patients with cancer and candidemia or deep-seated candidiasis treated with micafungin monotherapy was 81%. Intensive care unit (ICU) stay, concomitant nonfungal infections, and acute kidney injury were significantly associated with the 30-day crude mortality rate. Severe neutropenia was an independent predictor of micafungin failure. The efficacy and safety of micafungin in cancer patients with invasive candidiasis were comparable to those reported for patients without malignancy and for cancer patients treated with caspofungin.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Candidiasis
/
Echinocandins
/
Lipopeptides
/
Candidemia
/
Antifungal Agents
/
Neoplasms
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Antimicrob Agents Chemother
Year:
2014
Type:
Article